PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\', \'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\', \'Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.\', \'Department of Software and Information Systems Engineering, Ben Gurion University, Be\'er Sheva, Israel.\', \'Department of Biomedical Informatics, Harvard Medical School, Boston, MA.\', \'The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Tel Aviv, Israel.\', \'Department of Internal Medicine A, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\', \'Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; and.\', \'School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be\'er Sheva, Israel.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1182/blood.2021013768
?:hasPublicationType
?:journal
  • Blood
is ?:pmid of
?:pmid
?:pmid
  • 34662390
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.434
?:rankingScore_hIndex
  • 410
?:title
  • Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all